Peter Taylor

Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, UK

Peter C. Taylor holds the Norman Collison chair of musculoskeletal sciences at the University of Oxford and is a Fellow of St. Peter’s College. He is Head of Clinical Sciences at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. He was formerly Professor of Experimental Rheumatology at the Kennedy Institute of Rheumatology Division, Imperial College London and Dean of the Charing Cross campus. He studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge and his first degree was in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for research on pathogenesis of arthritis. In the summer of 2015 he was appointed medical director of the National Rheumatoid Arthritis Society, an outstanding patient led-charity. Professor Taylor chaired the UK government and NIHR Translational Research Partnership in rheumatology from 2015-18, an initiative bringing together the UK’s leading academic and clinical centres for experimental medicine and translational research into a ready-formed partnership of Universities and NHS hospitals. He was elected a distinguished member of the British Society for Rheumatogy in 2016 and delivered the Heberden Round that year.

Professor Taylor has specialist clinical interests in inflammatory arthritis. He has over 20 years’ experience in clinical trial design and international leadership in studies of biologic and small molecular therapies in rheumatoid arthritis and ankylosing spondylitis including the earliest seminal trails of anti-TNF and anti-IL-6 receptor therapy. In experimental medicine studies, Professor Taylor employs targeted therapies as probes of pathogenesis to investigate the in vivo biology of the target in the pathobiology of the disease phenotype under investigation. His related research expertise includes investigation of mechanisms sustaining inflammation and development of novel outcome measurements for application in assessment of response to therapy, including ultrasonographic, PET and high-field magnetic resonance imaging technology. His interest in novel outcome measures also includes new tools for the personalised assessment of well-being which can be used adjunctively to clinical outcome measures in informing management decisions.

Broadcast Time Zone is Central European Summer Time (CEST)

All registered delegates have been sent an invitation with personal link to set their profile and enter the virtual Congress platform. Your personal link will only be valid until the end of the Congress.  In order to view the Congress lectures and panel discussions, delegates must enter the virtual Congress platform and set their profile before the end of the Congress. For any additional information contact: